APM
ATXS

Avidity Partners Management’s Astria Therapeutics ATXS Stock Holding History

Avidity Partners Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-982,000
Closed -$13.8M – 89
2024
Q1 		$13.8M Buy
+982,000
New +$12.2M 0.45% 63

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Avidity Partners Management's ATXS Position: Q2 2024 in Review

Avidity Partners Management sold out of Astria Therapeutics (ATXS) in Q2 2024, closing a stake of 982,000 shares — an estimated $13.8M sold.

Avidity Partners Management first reported a position in ATXS in Q1 2024 and held it in 1 quarter. The position peaked at $13.8M in Q1 2024. 100 funds tracked by Wall St. Rank hold ATXS as of Q2 2024.

  • Avidity Partners Management reported no remaining Astria Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Avidity Partners Management sold 982,000 Astria Therapeutics shares in Q2 2024, an estimated $13.8M.
  • Avidity Partners Management first reported a position in Astria Therapeutics in Q1 2024 and held it in 1 quarter.
  • Avidity Partners Management's Astria Therapeutics position peaked at $13.8M in Q1 2024.
  • 100 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2024.

Based on Avidity Partners Management's 13F filing for Q2 2024, filed 14 Aug 2024.